INS and diabetes mellitus: The cost of hypoglycaemic agents for treating diabetes was €49.6 million (17% of total costs) (Table 5) of which €35.1 million (70%) represented insulin and analogues (A10A) and the rest oral glucose lowering drugs (A10B).